# DoD Increases GLP-1 Drug Orders

U.S. federal GLP-1 purchasing supporting military pharmacies reached 26,252 orders worth $235.2 million from January through September 2025—27% above the full-year 2024 dollar total. Since January 2024, 98.4% of recorded federal GLP-1 orders were routed through AmerisourceBergen Drug Corp., now Cencora. The figures indicate substantial demand and a concentrated distribution channel, not a newly announced solicitation; DoD procurement data also lag by roughly three quarters.

- The recorded 2025 order volume gives pharmaceutical distributors and manufacturers a demand signal for military pharmacy resupply, particularly as obesity-only brands increased to 40% of brand-named orders.
- The high share routed through Cencora highlights dependence on a primary distribution channel. Suppliers and procurement teams can use this concentration data when evaluating distribution capacity and supply-chain resilience.
- The reported $416.4 million in orders routed through Cencora since January 2024 is an aggregate purchasing figure, not a separately identified contract award. Businesses should not treat the data as an open solicitation.

**Jurisdictions:** federal
**Industries:** Healthcare
**Published:** November 22, 2026

### Government Entities
- U.S. Department of Defense (DoD)

### Vendors
- AmerisourceBergen Drug Corp. (now Cencora) (Pharmaceutical prime vendor and distributor for military pharmacy resupply)

### Sources
- [US military pharmacies ordered GLP-1 drugs 26,252 times in the first nine months of 2025 - every pen, vial, and tablet bottle a separate line in the federal procurement record. https://t.co/6HMT08iajc #pharma #altdata](https://x.com/ValanTechnology/status/2124465421277372677) - twitter-fed-procurement